Welcome to our dedicated page for Nektar Therapeutics SEC filings (Ticker: NKTR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Nektar Therapeutics filings document the regulatory record of a Delaware clinical-stage biotechnology issuer with common stock listed on the Nasdaq Capital Market under NKTR. The company's 8-K reports cover financial results, Regulation FD clinical disclosures for rezpegaldesleukin, material definitive agreements, underwriting arrangements, at-the-market equity distribution mechanics, and shelf-registration-related offerings.
Proxy materials describe annual meeting matters, director elections, equity incentive plan authorization, auditor ratification, executive compensation votes, and governance procedures. Nektar's filing record also reflects capital-structure disclosures for common stock and pre-funded warrants, clinical-stage pipeline risks, research and development funding needs, and public-company controls tied to its immunology drug development business.
NKTR: Notice of proposed insider sale and restricted‑stock vesting activity. The excerpt lists a proposed sale of 10,000 shares and related figures tied to the security, plus multiple past and scheduled restricted stock vesting events (examples: 2,991 vesting on 08/15/2025, 1,860 on 11/15/2021). The filing also records a sale by Howard Robin of 444 shares for $29,084.53.
Morgan Stanley Smith Barney LLC registered sale of 5,538 restricted stock units linked to common stock. The filing lists the RSU grant date 05/15/2021 and shows a prior disposition by Jonathan Zalevsky of 199 shares on 05/19/2026 for $13,036.49.
Nektar Therapeutics reported the results of its annual shareholder meeting held on June 4, 2026. Stockholders elected Howard W. Robin to the board to serve until the 2029 annual meeting, with 13,164,879 votes for, 4,975,288 against, and 286,175 abstentions, plus 4,588,835 broker non-votes.
Shareholders approved an amendment to the Amended and Restated 2017 Performance Incentive Plan to increase the shares of common stock authorized for issuance by 3,000,000 shares, with 13,160,661 votes for and 4,902,925 against. They also ratified Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026 by 22,591,556 votes for and 118,592 against. A non-binding advisory resolution approving the Company’s executive compensation received 18,154,226 votes for and 161,005 against.
Nektar Therapeutics reported that Interim CFO Linda M. Rubinstein filed an initial statement of beneficial ownership as a company officer. This Form 3 filing lists her as an officer but does not report any purchases, sales, or other transactions in Nektar Therapeutics securities.
Nektar Therapeutics' Chief R&D Officer Jonathan Zalevsky reported a small share sale primarily for tax purposes. On May 19, 2026, he sold 199 shares of common stock at a weighted average price of $65.51 per share to cover required tax withholding obligations linked to vesting restricted stock units. The filing states this did not represent a discretionary trade. Following the transaction, he directly held 20,975 shares of Nektar Therapeutics common stock.
Nektar Therapeutics President & CEO Howard W. Robin reported a small tax-related share sale. On this Form 4, he sold 444 shares of common stock at a weighted average price of $65.51 per share to cover required tax withholding obligations from vesting RSUs, which the company notes was not a discretionary trade.
After the sale, Robin directly holds 75,045 shares of Nektar common stock and has an additional 28 shares reported as indirectly owned through his spouse. The filing reflects routine equity compensation and related tax settlement rather than a change in his overall investment stance.
Biotechnology Value Fund and affiliated reporting persons amended a Schedule 13G to report beneficial ownership in Nektar Therapeutics common stock. As of the close of business on March 31, 2026, the Reporting Persons report holding an aggregate of specified positions, including 1,523,980 shares beneficially owned by BVF and 1,114,072 shares beneficially owned by BVF2. The filing states a denominator of 28,687,963 Shares outstanding as of March 11, 2026 used to compute percentages, and discloses 293,103 shares issuable upon exercise of Pre-Funded Warrants held by the Reporting Persons.
Nektar Therapeutics filed a prospectus supplement to offer up to $150,000,000 of common stock through an Equity Distribution Agreement with Guggenheim Securities, LLC and H.C. Wainwright & Co., LLC, enabling at-the-market sales from time to time. The sales agents will be paid a 3.0% commission and settlement is generally one business day after each sale.
The prospectus states an illustrative sale of 1,762,839 shares at an assumed price of $85.09 (last reported sale price on May 6, 2026), and discloses 33,786,032 shares outstanding as of April 30, 2026. Net proceeds are for general corporate purposes, including R&D and clinical development (notably Phase 3 trials for rezpegaldesleukin).